The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
Introduction. The use of doxorubicin in clinical practice has shown cumulative and dose-dependent toxic effects on cardiomyocytes, leading to an increase of mortality risk among patients with cancer and as a resulting to restrictions in the indications for its use.Text. A dangerous adverse reaction...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Language: | Russo |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2024-09-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/1913 |
| Tags: |
No Tags, Be the first to tag this record!
|